{"id":"https://openalex.org/W2000478369","doi":"https://doi.org/10.2174/092986610791760423","title":"Pyridoxamine, an Inhibitor of Advanced Glycation End Product (AGE) Formation Ameliorates Insulin Resistance in Obese, Type 2 Diabetic Mice","display_name":"Pyridoxamine, an Inhibitor of Advanced Glycation End Product (AGE) Formation Ameliorates Insulin Resistance in Obese, Type 2 Diabetic Mice","alternate_titles":[],"publication_year":2010,"publication_date":"2010-05-14","ids":{"openalex":"https://openalex.org/W2000478369","doi":"https://doi.org/10.2174/092986610791760423","mag":"2000478369","pmid":"https://pubmed.ncbi.nlm.nih.gov/20441560"},"language":"en","primary_location":{"id":"doi:10.2174/092986610791760423","doi":"https://doi.org/10.2174/092986610791760423","is_oa":false,"landing_page_url":"https://doi.org/10.2174/092986610791760423","pdf_url":null,"source":{"id":"https://openalex.org/S3577691","display_name":"Protein and Peptide Letters","issn_l":"0929-8665","issn":["0929-8665","1875-5305"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Protein &amp; Peptide Letters","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2000478369"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045554940","display_name":"Hiroyuki Unoki\u2010Kubota","orcid":"https://orcid.org/0000-0003-4827-8805","observed_orcids":["https://orcid.org/0000-0003-4827-8805"]},"institutions":[{"id":"https://openalex.org/I159385669","display_name":"Chiba University","ror":"https://ror.org/01hjzeq58","country_code":"JP","type":"education","lineage":["https://openalex.org/I159385669"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hiroyuki Unoki-Kubota","raw_affiliation_strings":["Division of Applied Translational Research, Chiba University Graduate School of Medicine, Chiba, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Applied Translational Research, Chiba University Graduate School of Medicine, Chiba, Japan","institution_ids":["https://openalex.org/I159385669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030113532","display_name":"Sho\u2010ichi Yamagishi","orcid":"https://orcid.org/0000-0003-0102-0823","observed_orcids":["https://orcid.org/0000-0003-0102-0823"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sho-ichi Yamagishi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015715722","display_name":"Masayoshi Takeuchi","orcid":"https://orcid.org/0000-0002-1057-3764","observed_orcids":["https://orcid.org/0000-0002-1057-3764"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Masayoshi Takeuchi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035797354","display_name":"Hideaki Bujo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hideaki Bujo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5103484910","display_name":"Yasushi Sait\u014d","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105296287","display_name":"Kurume University","ror":"https://ror.org/057xtrt18","country_code":"JP","type":"education","lineage":["https://openalex.org/I105296287"]}],"countries":["JP"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Yasushi Saito","raw_affiliation_strings":["Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume 830-0011, Japan.,Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume 830-0011, Japan.,Japan","institution_ids":["https://openalex.org/I105296287"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5103484910"],"corresponding_institution_ids":["https://openalex.org/I105296287"],"apc_list":null,"apc_paid":null,"fwci":2.4843,"has_fulltext":false,"cited_by_count":61,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.87737042,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"17","issue":"9","first_page":"1","last_page":"1181"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11142","display_name":"Advanced Glycation End Products research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1308","display_name":"Clinical Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11142","display_name":"Advanced Glycation End Products research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1308","display_name":"Clinical Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10528","display_name":"Adipokines, Inflammation, and Metabolic Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pyridoxamine","display_name":"pyridoxamine","score":1.0},{"id":"https://openalex.org/keywords/advanced-glycation-end-products","display_name":"advanced glycation end products","score":1.0},{"id":"https://openalex.org/keywords/insulin-resistance","display_name":"insulin resistance","score":0.9139999747276306},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9599999785423279},{"id":"https://openalex.org/keywords/obesity","display_name":"obesity","score":0.9909999966621399},{"id":"https://openalex.org/keywords/kk-ay-mice","display_name":"KK-Ay mice","score":0.8970000147819519},{"id":"https://openalex.org/keywords/insulin-sensitivity","display_name":"insulin sensitivity","score":0.6639999747276306},{"id":"https://openalex.org/keywords/fasting-insulin","display_name":"fasting insulin","score":0.5419999957084656},{"id":"https://openalex.org/keywords/diabetic-vascular-complications","display_name":"diabetic vascular complications","score":0.6940000057220459},{"id":"https://openalex.org/keywords/age-formation-inhibition","display_name":"AGE formation inhibition","score":0.6100000143051147}],"concepts":[{"id":"https://openalex.org/C2777391703","wikidata":"https://www.wikidata.org/wiki/Q1053470","display_name":"Insulin resistance","level":3,"score":0.8620182275772095},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.8339608907699585},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.8055275082588196},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.706945538520813},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.676264226436615},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.6449097990989685},{"id":"https://openalex.org/C147990577","wikidata":"https://www.wikidata.org/wiki/Q25790","display_name":"Glycation","level":3,"score":0.6159253716468811},{"id":"https://openalex.org/C2776997535","wikidata":"https://www.wikidata.org/wiki/Q2556837","display_name":"Advanced glycation end-product","level":4,"score":0.5864733457565308},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.522931694984436},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.4100547730922699}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D007333","descriptor_name":"Insulin Resistance","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009765","descriptor_name":"Obesity","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D009765","descriptor_name":"Obesity","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D011733","descriptor_name":"Pyridoxamine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D017127","descriptor_name":"Glycation End Products, Advanced","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D017127","descriptor_name":"Glycation End Products, Advanced","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.2174/092986610791760423","doi":"https://doi.org/10.2174/092986610791760423","is_oa":false,"landing_page_url":"https://doi.org/10.2174/092986610791760423","pdf_url":null,"source":{"id":"https://openalex.org/S3577691","display_name":"Protein and Peptide Letters","issn_l":"0929-8665","issn":["0929-8665","1875-5305"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Protein &amp; Peptide Letters","raw_type":"journal-article"},{"id":"doi:10.2174/0929210204415608665","doi":"https://doi.org/10.2174/0929210204415608665","is_oa":false,"landing_page_url":"https://doi.org/10.2174/0929210204415608665","pdf_url":null,"source":{"id":"https://openalex.org/S3577691","display_name":"Protein and Peptide Letters","issn_l":"0929-8665","issn":["0929-8665","1875-5305"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Protein and Peptide Letters","raw_type":"journal-article"},{"id":"pmid:20441560","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20441560","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Protein and peptide letters","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2074891815","https://openalex.org/W2082405850","https://openalex.org/W2112388240","https://openalex.org/W1988304421","https://openalex.org/W2061906058","https://openalex.org/W2363890520","https://openalex.org/W2056394835","https://openalex.org/W2804245722","https://openalex.org/W2023279316","https://openalex.org/W2123032423"],"abstract_inverted_index":{"There":[0],"is":[1,63],"a":[2,87,184],"growing":[3],"body":[4],"of":[5,12,56,77,90,100,124,137,151,170,179],"evidence":[6],"that":[7],"the":[8,53,110,168],"formation":[9,79,181],"and":[10,49,102,144],"accumulation":[11],"advanced":[13],"glycation":[14],"end":[15],"products":[16],"(AGE)":[17],"have":[18,38],"been":[19],"known":[20],"to":[21,118],"progress":[22],"under":[23],"diabetic":[24,30],"conditions,":[25],"thereby":[26],"being":[27],"involved":[28],"in":[29,46,58,61,68,84,104,133,148,172,175,192],"vascular":[31],"complications.":[32],"Further,":[33],"we,":[34],"along":[35],"with":[36,129,194],"others,":[37],"recently":[39],"found":[40],"AGE":[41,57,78,103,125,171,180],"could":[42,80],"disturb":[43],"insulin":[44,59,82,101,130,142,146,173,190],"actions":[45],"cultured":[47],"adipocytes":[48],"skeletal":[50],"muscles.":[51],"However,":[52],"pathological":[54],"role":[55],"resistance":[60,83,174,191],"vivo":[62],"not":[64,158],"fully":[65],"understood.":[66],"Therefore,":[67],"this":[69],"study,":[70],"we":[71],"examined":[72],"whether":[73],"pyridoxamine,":[74],"an":[75],"inhibitor":[76],"ameliorate":[81],"KK-A(y)":[85,105,134,149,176],"mice,":[86],"model":[88],"animal":[89],"obese,":[91],"type":[92],"2":[93],"diabetes.":[94],"Fasting":[95],"blood":[96,161],"glucose,":[97],"serum":[98],"levels":[99,123,143],"mice":[106,111,150],"were":[107,126],"elevated":[108],"as":[109],"got":[112],"older":[113],"(from":[114],"5":[115],"weeks":[116,120,153],"old":[117],"15":[119],"old).":[121],"Serum":[122],"positively":[127],"correlated":[128],"(R(2)=0.3956,":[131],"P=0.002)":[132],"mice.":[135,177],"Administration":[136],"pyridoxamine":[138],"dose-dependently":[139],"decreased":[140],"fasting":[141,160],"improved":[145],"sensitivity":[147],"10":[152],"old,":[154],"although":[155],"it":[156],"did":[157],"affect":[159],"glucose":[162],"levels.":[163],"Our":[164],"present":[165],"study":[166],"suggests":[167],"involvement":[169],"Inhibition":[178],"may":[182],"be":[183],"novel":[185],"therapeutic":[186],"target":[187],"for":[188],"improving":[189],"diabetes":[193],"obesity.":[195]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2000478369","counts_by_year":[{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":5},{"year":2014,"cited_by_count":3},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
